Triple Negative Breast Cancer Therapy Resistance and Metastasis
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 5 November 2024 | Viewed by 2582
Special Issue Editor
Special Issue Information
Dear Colleagues,
Breast cancer (BC) is the most common type of cancer diagnosed in women worldwide. Around 10% of patients with BC are diagnosed with the Triple-Negative Breast Cancer (TNBC) subtype. Such subtype lacks the expression of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2, thus limiting the therapeutic options for patients with TNBC.
TNBC is associated with a poor prognosis due to the high systemic recurrence and lack of response to conventional therapies, especially at an advanced stage of the disease. Moreover, patients with TNBC often develop therapy resistance and metastasis, negatively affecting patients’ survival rate.
As revealed by proteomics and transcriptomics, this specific clinical group of patients is highly heterogenous, comprising of distinct histological and molecular biomarkers. Therefore, identifying the most effective treatment/combination of therapeutic strategies that could effectively fight the disease and the occurrence of metastasis has been a major challenge in the clinics.
This Special Issue will focus on the current therapeutic approaches adopted to tackle TNBC and the progression of the disease, as well as the efforts made to uncover novel therapeutic targets and schemes, which ultimately will increase the survival rate of patients with TNBC. Here, we welcome both original or review articles in basic science, pre-clinical studies, clinical studies and translational medicine.
Dr. Daniela Sousa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TNBC
- therapeutic resistance
- immunotherapy
- metastasis
- personalized medicine
- targeted therapies
- adjuvant therapies
- neoadjuvant therapies